Congruence

ImpriMed, founded in 2017 in California, develops AI-driven cancer treatment technology for dogs and cats, helping veterinarians identify the most suitable drugs for individual animals with blood cancers, with the goal of extending its precision medicine technology to human oncology.

Series A · $23M · 2023-12

Evozyne, founded in 2020 in Chicago, provides a generative AI platform for drug discovery and drug development.

Undisclosed · $81M · 2023-09

TwoStep Therapeutics is a Stanford University spin-out founded in 2024 and headquartered in San Carlos, California, developing peptide-drug conjugates and radioligand therapies for solid tumors built on its polyspecific integrin-binding peptide (PIP) platform.

Series A · $71M · 2026-09

Innovative-drug developer using genetics and AI to discover first-in-class targets

Series D+ · $55M · 2026-07

MindRank (德睿智药, Hangzhou MindRank Technology Co., Ltd.), founded in 2020, is a clinical-stage AI-native drug discovery company that has developed a proprietary end-to-end AI pharmaceutical engine called MAP (Molecule Arts Platform), leveraging multi-agent collaboration and clinical data feedback loops to tackle hard-to-drug targets. Its oral GLP-1RA small molecule MDR-001 reportedly achieved 10.3% weight reduction at 24 weeks in a Phase IIb trial and has advanced to Phase III. The company is headquartered in Hangzhou.

Series B · $52M · 2026-07

Purui Chuangzhi is a technology company that uses AI to transform pharmaceutical clinical trials, offering an end-to-end intelligent clinical trial platform featuring automated data flow, AI-driven decision-making, and built-in compliance throughout. The company has served nearly 300 domestic and international pharmaceutical enterprises and completed close to 600 Phase 1-3 registration and real-world study projects.

Series A · $14M · 2026-06

Aqemia, founded in 2019 in Paris, France, uses generative AI and quantum physics to discover cancer drugs, differentiating itself by not requiring experimental chemistry data to train its models during the design phase.

Undisclosed · $71M · 2024-12

Causaly, founded in 2017 in London, UK, builds an AI platform to help researchers accelerate drug development and testing, partnering with 12 of the world's largest pharmaceutical companies and multiple medical research institutions.

Series B · $60M · 2023-07

Turbine, founded in 2015 in London, UK (with offices in Budapest and other locations), uses AI to simulate biological experiments to accelerate drug discovery and translational research.

Series B · $25M · 2026-03

Galux, founded in 2020 in Seoul, operates GaluxDesign, an AI and physics-based platform for protein and antibody design in drug development.

Series B · $58M · 2026-02

According to a TechCrunch report dated July 14, 2026 (source unspecified), former OpenAI researcher Miles Wang is preparing to launch an AI drug discovery startup. The company name, headquarters, and website remain undisclosed, and the funding details are unconfirmed rumors.

Founded in 2026 and based in Lund, Sweden (YC Fall 2026), Halmos Labs builds automated, AI-driven R&D systems for biotech: it simulates experimental outcomes across multiple models, methods and assumptions before wet-lab execution so researchers can pick the experiment that most reduces uncertainty, reaching validated conclusions with fewer experiments. Use cases include drug discovery, process and assay development and manufacturing optimization; first product is Halmos Bio.